Revelation Biosciences Inc

Revelation Biosciences, Inc. is a clinical-stage life science company focused on rebalancing inflammation to optimize health. Its lead product candidate, Gemini, is a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), a Toll-like receptor 4 (TLR) agonist that modulates and rebalances dysregulated inflammatory responses. The company develops and commercializes therapeutics that modulate the innate immune system, including GEM-AKI for acute kidney injury and GEM-CKD for chronic kidney disease. Formerly known as Petra Acquisition, Inc., it changed its name to Revelation Biosciences, Inc. in January 2022, was incorporated in 2019, and is based in San Diego, California.